<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365344">
  <stage>Registered</stage>
  <submitdate>19/11/2013</submitdate>
  <approvaldate>22/11/2013</approvaldate>
  <actrnumber>ACTRN12613001304729</actrnumber>
  <trial_identification>
    <studytitle>A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants </studytitle>
    <scientifictitle>A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants </scientifictitle>
    <utrn>U1111-1150-5237 </utrn>
    <trialacronym>ARES Collaborative</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Significant haemorrhage</healthcondition>
    <healthcondition>Thromboembolism</healthcondition>
    <healthcondition>Urgent surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational study to document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage, thromboembolism or require anticoagulant reversal for urgent surgery and/or a procedure  whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. The duration of the study is 42 months. </interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To observe the current practice for achieving haemostasis in 2000 patients who present with significant haemorrhage or urgent surgery whilst on new (dabigatran, rivaroxaban, apixaban or endoxaban) or established (warfarin) oral anticoagulants. Data will be collected by reviewing patients medical records.</outcome>
      <timepoint>42 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In patients whilst on oral anticoagulants who present with embolism, determine the circumstances and level of anticoagulation at the time of presentation.  Data will be collected by reviewing patients medical records.</outcome>
      <timepoint>42 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting with significant haemorrhage, thromboembolism or require anticoagulation reversal for urgent surgery and/or a procedure and have taken a NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin within the last 7 days.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who have minor haemorrhage responding to local measures not requiring admission, blood testing or change in anticoagulant management.

Patients who are unable to have objective testing for recurrence of thromboembolism.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Around 240,000 Australian patients are currently on OAC of which around 13% are on a new oral anticoagulant (NOAC). Major bleeding occurs in 2-3% of patients on OAC and embolism in 1-2% per year. 2000 patients will be recruited to obtain a cross-sectional sample to document the standard of care for these patients.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>True</patientregistry>
    <followup>30</followup>
    <followuptype>Days</followuptype>
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/05/2012</anticipatedstartdate>
    <actualstartdate>20/05/2012</actualstartdate>
    <anticipatedenddate>30/09/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>2000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>ARES Collaborative</primarysponsorname>
    <primarysponsoraddress>c/o The Perth Blood Institute
Hollywood Specialist Centre
Suite 3/95 Monash Avenue
Nedlands
WA 6009 
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australasian Society of Thrombosis and Haemostasis (ASTH)</fundingname>
      <fundingaddress>PO Box 217 
Glen Iris 
Victoria 3146
Australia </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>ASTH</sponsorname>
      <sponsoraddress>PO Box 217
Glen Iris
Victoria 3146
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage or require anticoagulant reversal for urgent surgery and/or a procedure whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. In patients whilst on oral anticoagulants who present with embolism, determine the circumstances and level of anticoagulation at the time of presentation.</summary>
    <trialwebsite>www.aptin.org</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital HREC</ethicname>
      <ethicaddress>Level 5, Colonial House
Royal Perth Hospital
Murray Street
Perth WA 6000
</ethicaddress>
      <ethicapprovaldate>1/05/2012</ethicapprovaldate>
      <hrec>2012/071</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Local Health District HREC</ethicname>
      <ethicaddress>Concord Repatriation General Hospital
Building 75, Hospital Road
Concord, NSW 2139</ethicaddress>
      <ethicapprovaldate>30/08/2012</ethicapprovaldate>
      <hrec>HREC/12/CRGH/102</hrec>
      <ethicsubmitdate>28/06/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ross Baker</name>
      <address>The Perth Blood Institute
Hollywood Medical Centre
Suite 37/85 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 892002236</phone>
      <fax />
      <email>info@aptin.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Wendy Angelatos</name>
      <address>The Perth Blood Institute Hollywood Specialist Centre, Suite 3/95 Monash Avenue Nedlands WA 6009  </address>
      <phone>+61 892004904</phone>
      <fax />
      <email>info@aptin.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ross Baker</name>
      <address>The Perth Blood Institute
Hollywood Medical Centre
Suite 37/85 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 892002236</phone>
      <fax />
      <email>info@aptin.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Wendy Angelatos</name>
      <address>The Perth Blood Institute, Hollywood Specialist Centre, Suite 3/95 Monash Avenue, Nedlands, WA 6009   </address>
      <phone>+61 892004904</phone>
      <fax />
      <email>info@aptin.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>